Diasome

A clinical-stage biopharma company advancing portal hepatic-targeted therapies to transform how metabolic diseases are treated.

[Diasome @Diasome]

Better glycemic control in T1D has typically meant greater hypoglycemia risk. Our phase 2b data show investigational HDV™-Insulin Lispro significantly reduced hypoglycemia versus control group. See full study results https://t.co/ea6gdyfdqT

[Diasome @Diasome]

Bob Geho sat down with CareTalk to unpack our OPTI-2 results from #ADASciSessions2026, and what they could mean for people with T1D who deserve better than a 30-year tradeoff. Listen to the podcast: https://t.co/0VD4wlE1Lo

[Diasome @Diasome]

Hepatocytes make up ~80% of the liver and regulate glucose, lipids, and metabolic signals. When therapies act there directly, outcomes may improve. OPTI-2 Phase 2b results presented at ADA show clinical evidence of what that looks like. https://t.co/s2iicpYqzx

[Diasome @Diasome]

Our HDV hepatic-targeting platform extends beyond insulin to include GLP and Serotonin programs in development, each building on our clinically validated approach to address the underlying drivers of metabolic disease. https://t.co/VbfQb1CQpF

[Diasome @Diasome]

At ADA today, Diasome presented Phase 2b results from OPTI-2. HDV-insulin lispro maintained A1C while significantly reducing hypoglycemia, without the tradeoffs that have defined insulin therapy for over 30 years. Full results: https://t.co/ON75XkAtJN

[Diasome @Diasome]

What if metabolic therapies could go exactly where they're needed? Diasome's HDV platform targets liver cells directly, supporting insulin, GLP-1, serotonin, and more. Clinical data coming soon. Learn more about HDV: https://t.co/3D5RXhhenJ

[Diasome @Diasome]

Diasome will present Phase 2b data from OPTI-2 at ADA's 86th Scientific Sessions in New Orleans on June 7. The 25-week RCT in adults with T1D tests whether changing where insulin acts can improve glycemic control without raising hypoglycemia risk. https://t.co/uNbNaA8GVW

[Diasome @Diasome]

The liver is the body's primary metabolic regulator, and often where metabolic disease is centered. Healthy insulin signaling starts there, too. When therapies bypass that pathway, efficacy may suffer. Diasome's HDV platform is designed to act there first. https://t.co/3D5RXhhenJ

[Diasome @Diasome]

Better glucose control shouldn't mean a higher risk of hypoglycemia. For people with type 1 diabetes, this tradeoff has persisted for over 30 years. At Diasome, we believe patients deserve better options. https://t.co/s2iicpYYp5

[Diasome @Diasome]

Diasome’s HDV technology is an insulin additive being developed to prevent #hypoglycemia by restoring normal liver physiology in people with #diabetes. Learn more here: https://t.co/75hCdtttYt

[Diasome @Diasome]

Are you looking to get involved, take action and join in the fight against #diabetes? The @AmDiabetesAssn is a great resource for ways to help raise awareness: https://t.co/AN9NqCfx1f

[Diasome @Diasome]

#DYK that according to the @ADA_Journals, the global economic burden of #diabetes will increase to $2.1 trillion by 2030? Learn about how we're rethinking #insulin to lessen the burden here: https://t.co/wrk78TATMY

[Diasome @Diasome]

We recently presented our corporate overview at the Summer 2020 Private Company Showcase hosted by @SoleburyTrout. To check out our presentation, click here: https://t.co/FRKYeVUw4Q

[Diasome @Diasome]

New #research finds that kids at risk for #diabetes can now be tested more easily by measuring A1C. Find out more in this article by Sabrina Emms at @medicaldaily: https://t.co/vhWE6PCGeo

[Diasome @Diasome]

People with #T1D have to strike a balance between reaching target blood glucose levels and increasing their hypoglycemia risk. Learn more about the additive we're developing to improve insulin's efficacy & safety by clicking here: https://t.co/0gaLGB1baf

[Diasome @Diasome]

We have developed a nanoscale, frisbee-shaped carrier known as #HDV that delivers roughly 100 #insulin molecules per disc to the #liver. To learn more about our new breakthrough #diabetes technology, click here: https://t.co/eO36Vyv63E

[Diasome @Diasome]

#DYK that the average person with T1D experiences symptomatic hypoglycemia twice per week? We're working to remedy that by developing a new liver targeted nanotechnology. Learn more here: https://t.co/MECSjHGpgz Diasome: #WeTellInsulinWhereToGo

[Diasome @Diasome]

To date, most developers have only focused on how much and how fast insulin acts in the body. Our HDV technology directs insulin where it needs to go: the liver. Learn more here: https://t.co/wSaPipifck #WeTellInsulinWhereToGo

[Diasome @Diasome]

#DYK that more than 79% of people living with #T1D don't achieve the @AmDiabetesAssn's recommended #A1C target? Learn more about our goal to create a more targeted #insulin therapy aiming at re-engaging the #liver here: https://t.co/4ZJzA8vnWr

[Diasome @Diasome]

In times of heightened stress, people with #diabetes may find it increasingly difficult to manage their blood sugar. Find out more in this article by @SerenaG1 with @HealthDayTweets: https://t.co/asjrhd3iLf